Skip to main content
All lobbying filings

BRISTOL-MYERS SQUIBB COMPANY

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $870,000.00 expenses · posted Apr 20, 2025

Official filing document

 Bills named in this filing 8
 Lobbying activity 5
Health Issues

Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Copyright/Patent/Trademark

Intellectual Property Reform concerning bio-pharmaceutical industry

Pharmacy

H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem